Table 1.
Demographic information and patient characteristics.
| Prior Embolization (n = 61) |
Embolization-Naïve (n = 110) | |
|---|---|---|
| Gender | ||
| Male | 34 (56%) | 61 (56%) |
| Female | 27 (44%) | 49 (44%) |
| Age at PRRT | ||
| Mean (SD) | 64.2 (10) | 64.4 (8.9) |
| Follow-up Time (months) | ||
| Mean (SD) | 22.4 (11.4) | 20.9 (10.4) |
| Years From Diagnosis to PRRT | ||
| Mean (SD) | 7.2 (5.5) | 6.4 (5.8) |
| Primary Tumor Location | ||
| Foregut | 3 (5%) | 6 (5%) |
| Midgut | 43 (71%) | 57 (52%) |
| Hindgut | 2 (3%) | 7 (6%) |
| Pancreas | 11 (18%) | 33 (30%) |
| Other/Unknown | 2 (3%) | 7 (7%) |
| Tumor Grade | ||
| 1 | 19 (31%) | 42 (38%) |
| 2 | 29 (48%) | 52 (47%) |
| 3 | 8 (13%) | 6 (6%) |
| Uncertain | 5 (8%) | 10 (9%) |
| Tumor Burden | ||
| <25% | 40 (66%) | 90 (82%) |
| 25–50% | 16 (26%) | 15 (14%) |
| >50% | 5 (8%) | 5 (5%) |
| PRRT Cycles | ||
| 1 | 0 (0%) | 3 (3%) |
| 2 | 5 (8%) | 4 (4%) |
| 3 | 6 (10%) | 10 (9%) |
| 4 | 50 (82%) | 93 (84%) |
Abbreviations: PRRT = peptide receptor radionuclide therapy.